このページの翻訳は実験的なもので、現在開発中です。お待ちしております

Dyne Therapeutics 将来の成長

Future 基準チェック /26

Dyne Therapeutics利益と収益がそれぞれ年間19.8%と60.4%増加すると予測されています。EPS は年間増加すると予想されています。自己資本利益率は 3 年後に-126.9% 29.5%なると予測されています。

主要情報

13.5%

収益成長率

20.8%

EPS成長率

Biotechs 収益成長	28.7%
収益成長率	66.8%
将来の株主資本利益率	-44.6%
アナリストカバレッジ	Good
最終更新日	23 Sep 2024

今後の成長に関する最新情報

Recent updates

Dyne Therapeutics: Management Merry-Go-Round, Shaky Data Rock Wall Street

Sep 04

Companies Like Dyne Therapeutics (NASDAQ:DYN) Are In A Position To Invest In Growth

Aug 14

We Think Dyne Therapeutics (NASDAQ:DYN) Needs To Drive Business Growth Carefully

Dec 10

Is Dyne Therapeutics (NASDAQ:DYN) In A Good Position To Invest In Growth?

Aug 26

Dyne wins regulatory nod to start trial for myotonic dystrophy candidate

Jul 12

Dyne stock rises 12% as FDA lifts hold on starting muscle disorder study of DYNE-251

Jul 05

Here's Why We're Watching Dyne Therapeutics' (NASDAQ:DYN) Cash Burn Situation

May 05

We're Hopeful That Dyne Therapeutics (NASDAQ:DYN) Will Use Its Cash Wisely

Jan 12

We Think Dyne Therapeutics (NASDAQ:DYN) Can Afford To Drive Business Growth

Sep 29

Dyne Therapeutics' chief scientific officer Romesh Subramanian steps down

Jun 02

Here's Why We're Not Too Worried About Dyne Therapeutics' (NASDAQ:DYN) Cash Burn Situation

May 12

Dyne Therapeutics EPS beats by $0.10

May 06

Could The Dyne Therapeutics, Inc. (NASDAQ:DYN) Ownership Structure Tell Us Something Useful?

Jan 27

業績と収益の成長予測

NasdaqGS:DYN - アナリストの将来予測と過去の財務データ ( )USD Millions
日付	収益	収益	フリー・キャッシュフロー	営業活動によるキャッシュ	平均アナリスト数
12/31/2026	11	-335	-320	-279	6
12/31/2025	1	-315	-295	-250	9
12/31/2024	N/A	-273	-280	-251	9
6/30/2024	N/A	-258	-220	-219	N/A
3/31/2024	N/A	-257	-220	-220	N/A
12/31/2023	N/A	-236	-189	-188	N/A
9/30/2023	N/A	-208	-184	-182	N/A
6/30/2023	N/A	-189	-176	-175	N/A
3/31/2023	N/A	-177	-152	-150	N/A
12/31/2022	N/A	-168	-157	-154	N/A
9/30/2022	N/A	-181	-157	-153	N/A
6/30/2022	N/A	-182	-141	-137	N/A
3/31/2022	N/A	-160	-157	-152	N/A
12/31/2021	N/A	-149	-123	-120	N/A
9/30/2021	N/A	-126	-114	-112	N/A
6/30/2021	N/A	-97	-98	-96	N/A
3/31/2021	N/A	-77	-59	-58	N/A
12/31/2020	N/A	-59	-48	-47	N/A
9/30/2020	N/A	-36	-32	-30	N/A
6/30/2020	N/A	-28	-23	-22	N/A
3/31/2020	N/A	-21	-18	-17	N/A
12/31/2019	N/A	-15	-13	-12	N/A

アナリストによる今後の成長予測

収入対貯蓄率: DYN今後 3 年間、利益が出ない状態が続くと予測されています。

収益対市場: DYN今後 3 年間、利益が出ない状態が続くと予測されています。

高成長収益: DYN今後 3 年間、利益が出ない状態が続くと予測されています。

収益対市場: DYNの収益 ( 60.4% ) US市場 ( 8.7% ) よりも速いペースで成長すると予測されています。

高い収益成長: DYNの収益 ( 60.4% ) 20%よりも速いペースで成長すると予測されています。

一株当たり利益成長率予想

将来の株主資本利益率

将来のROE: DYN 3 年以内に赤字になると予測されています。

Dyne Therapeutics 将来の成長

Future 基準チェック /26

主要情報

今後の成長に関する最新情報

Price target increased by 8.9% to US$50.00

Price target increased by 8.3% to US$37.56

Price target increased by 9.6% to US$28.50

Price target decreased to US$24.67

Price target decreased to US$30.25

Recent updates

CEO, President & Director recently bought US$1.1m worth of stock

Dyne Therapeutics: Management Merry-Go-Round, Shaky Data Rock Wall Street

Dyne Therapeutics, Inc Announces Management Changes

Companies Like Dyne Therapeutics (NASDAQ:DYN) Are In A Position To Invest In Growth

Price target increased by 8.9% to US$50.00

Chief Operating Officer notifies of intention to sell stock

Dyne Therapeutics, Inc. Presents New Preclinical Data for its Facioscapulohumeral Muscular Dystrophy Program During the FSHD Society International Research Congress

Chief Operating Officer notifies of intention to sell stock

Dyne Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $325.5 million.

New major risk - Shareholder dilution

Chief Scientific Officer notifies of intention to sell stock

Dyne Therapeutics: Progress Undenied In DM1 And DMD Trials

Dyne Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $300 million.

We're Not Very Worried About Dyne Therapeutics' (NASDAQ:DYN) Cash Burn Rate

Dyne Therapeutics, Inc., Annual General Meeting, May 22, 2024

Dyne Therapeutics, Inc. Announces Chief Executive Officer Changes

CEO, President & Director recently sold US$223k worth of stock

Chief Operating Officer recently sold US$725k worth of stock

Price target increased by 8.3% to US$37.56

Dyne: H2 2024 Muscle Disease Data Could Boost Value

Dyne Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $200 million.

CEO, President & Director notifies of intention to sell stock

Chief Business Officer exercised options and sold US$476k worth of stock

New major risk - Shareholder dilution

Dyne Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $300.125 million.

Dyne Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $300.125 million.

Dyne Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $175 million.

Chief Business Officer notifies of intention to sell stock

We're Keeping An Eye On Dyne Therapeutics' (NASDAQ:DYN) Cash Burn Rate

Chief Operating Officer notifies of intention to sell stock

New major risk - Financial position

CEO, President & Director notifies of intention to sell stock

Here's Why We're Watching Dyne Therapeutics' (NASDAQ:DYN) Cash Burn Situation

New major risk - Financial position

Insufficient new directors

CEO, President & Director recently sold US$618k worth of stock

CEO, President & Director notifies of intention to sell stock

Dyne Therapeutics, Inc. Announces Resignation of Dr. Lawrence Klein as Board Member

Insufficient new directors

We're Keeping An Eye On Dyne Therapeutics' (NASDAQ:DYN) Cash Burn Rate

Price target increased by 9.6% to US$28.50

Insider exercised options and sold US$133k worth of stock

Insider notifies of intention to sell stock

We Think Dyne Therapeutics (NASDAQ:DYN) Needs To Drive Business Growth Carefully

Dyne Therapeutics, Inc. Receives Fda Fast Track Designation for Dyne-251 for the Treatment of Duchenne Muscular Dystrophy

CEO, President & Director exercised options and sold US$2.4m worth of stock

Dyne Therapeutics, Inc. Presents Preclinical Data from Its Duchenne Muscular Dystrophy Programs Targeting Exons 51 and 53 At World Muscle Society 2022 Congress

Dyne Therapeutics, Inc. Prioritizes its Focus and Resources on its Clinical Programs, DYNE-101 in DM1 and DYNE-251 in DMD

Dyne Therapeutics Announces Initiation of Phase 1/2 ACHIEVE Clinical Trial of DYNE-101 for the Treatment of Myotonic Dystrophy Type 1

Dyne Therapeutics, Inc. Appoints Francesco Bibbiani as Senior Vice President, Head of Development

Is Dyne Therapeutics (NASDAQ:DYN) In A Good Position To Invest In Growth?

Dyne Therapeutics, Inc. Announces “Breakthrough Article” Publication of Duchenne Muscular Dystrophy Program Data in Nucleic Acids Research

High number of new directors

Price target decreased to US$24.67

Dyne Therapeutics Announces Clearance of Clinical Trial Application for DYNE-101 for the Treatment of Myotonic Dystrophy Type 1

Dyne wins regulatory nod to start trial for myotonic dystrophy candidate

Dyne Therapeutics, Inc. Announces FDA Clearance of IND Application for DYNE-251 for the Treatment of Duchenne Muscular Dystrophy

Dyne stock rises 12% as FDA lifts hold on starting muscle disorder study of DYNE-251

Dyne Therapeutics, Inc. Presents New In Vivo Data from DYNE-101

Here's Why We're Watching Dyne Therapeutics' (NASDAQ:DYN) Cash Burn Situation

High number of new directors

Dyne Therapeutics, Inc., Annual General Meeting, Jun 03, 2022

Price target decreased to US$30.25

Dyne Therapeutics, Inc. Appoints Carlo Inert, M.D., to Its Board of Directors

Dyne Therapeutics Announces FDA Clinical Hold on IND Application for DYNE-251 in Duchenne Muscular Dystrophy

We're Hopeful That Dyne Therapeutics (NASDAQ:DYN) Will Use Its Cash Wisely

Dyne Therapeutics, Inc. Announces Submission of IND Application to Initiate Clinical Trial of DYNE-251 for Duchenne Muscular Dystrophy

We Think Dyne Therapeutics (NASDAQ:DYN) Can Afford To Drive Business Growth

Dyne Therapeutics, Inc.(NasdaqGS:DYN) dropped from Russell 3000E Growth Index

Dyne Therapeutics, Inc. Presents Preclinical Data from Its Facioscapulohumeral Muscular Dystrophy Program During the FSHD Society International Research Congress